The pharmaceutical industry’s core defense of American drug prices is that research and development is expensive, risky, and requires the returns that high prices generate. The documented reality is more complicated. The foundational research underlying most major drugs was funded by the National Institutes of Health — meaning American taxpayers — before private manufacturers acquired licensing rights and set prices. Marketing budgets at major pharmaceutical companies routinely exceed research budgets. The riskiest early-stage research is publicly subsidized. The profitable commercialization is private. The patient pays twice — once through taxes that funded the research and again at the pharmacy counter.
This is not an argument against pharmaceutical innovation. It is a documented account of how the current system allocates risk and reward — and who bears the cost of that allocation. Americans pay two to three times more for the same drugs than people in peer countries not because American patients receive better drugs or more of them but because the pricing system operates without the negotiating mechanisms that every other wealthy country uses as a matter of course.
Patent evergreening extends effective monopoly pricing on existing drugs by years or decades through minor reformulations that trigger new exclusivity periods. The Hatch-Waxman generic pathway was designed to introduce price competition after patent expiration — and has been systematically gamed to delay it. Pharmacy benefit managers sit between manufacturers and patients extracting margin from both while remaining largely invisible to the people whose drug costs they determine.
This hub documents how pharmaceutical pricing works, how the R&D argument holds up under scrutiny, who benefits from the current structure, and what serious reform proposals are on the table. It does not advocate for a specific policy path. It provides the documented record that informed deliberation requires.